Co-D Therapeutics Granted Orphan Designation for Triolimus for the Treatment of Angiosarcoma

Co-D Therapeutics, Inc., a pre-clinical stage pharmaceutical company developing agents for the treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) has granted Co-D’s request for orphan drug designation of Triolimus for the treatment of the highly lethal malignancy, angiosarcoma. “We are pleased that Triolimus has been designated an orphan drug for […]